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SHORT ABSTRACT: 74 
Here we explain a protocol for modelling the biophysical microenvironment where crosslinking 75 
and increased stiffness of the basement membrane (BM) induced by advanced glycation 76 
endproducts (AGEs) has pathological relevance.  77 
 78 
LONG ABSTRACT: 79 
Here we describe a protocol that can be used to study the biophysical microenvironment 80 
related to increased thickness and stiffness of the basement membrane (BM) during age-81 
related pathologies and metabolic disorders (e.g. cancer, diabetes, microvascular disease, 82 
retinopathy, nephropathy and neuropathy). The premise of the model is non-enzymatic 83 
crosslinking of reconstituted BM (rBM) matrix by treatment with glycolaldehyde (GLA) to 84 
promote advanced glycation endproduct (AGE) generation via the Maillard reaction. Examples 85 
of laboratory techniques that can be used to confirm AGE generation, non-enzymatic 86 
crosslinking and increased stiffness in GLA treated rBM are outlined. These include preparation 87 
of native rBM (treated with phosphate-buffered saline, PBS) and stiff rBM (treated with GLA) 88 
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for determination of: its AGE content by photometric analysis and immunofluorescent 89 
microscopy, its non-enzymatic crosslinking by sodium dodecyl sulfate polyacrylamide gel 90 
electrophoresis (SDS PAGE) as well as confocal microscopy, and its increased stiffness using 91 
rheometry. The procedure described here can be used to increase the rigidity (elastic moduli, E) 92 
of rBM up to 3.2-fold, consistent with measurements made in healthy versus diseased human 93 
prostate tissue. To recreate the biophysical microenvironment associated with the aging and 94 
diseased prostate gland three prostate cell types were introduced on to native rBM and stiff 95 
rBM: RWPE-1, prostate epithelial cells (PECs) derived from a normal prostate gland; BPH-1, 96 
PECs derived from a prostate gland affected by benign prostatic hyperplasia (BPH); and PC3, 97 
metastatic cells derived from a secondary bone tumor originating from prostate cancer. 98 
Multiple parameters can be measured, including the size, shape and invasive characteristics of 99 
the 3D glandular acini formed by RWPE-1 and BPH-1 on native versus stiff rBM, and average cell 100 
length, migratory velocity and persistence of cell movement of 3D spheroids formed by PC3 101 
cells under the same conditions. Cell signaling pathways and the subcellular localization of 102 
proteins can also be assessed.  103 
 104 
INTRODUCTION: 105 
The basement membrane (BM) is a sheet of specialized extracellular matrix (ECM) that 106 
maintains stable tissue borders by separating layers of epithelial cells from the stroma1. 107 
Covalent crosslinking between adjacent triple helices of collagen IV in the BM stabilizes their 108 
lateral association by establishing an irregular network of super-twisted helices2. These collagen 109 
IV lattices act as a scaffold for its interaction with laminin and other BM components1. The 110 
structural arrangement of the BM provides it with the mechanical strength and rigidity 111 
necessary for the normal development of glandular epithelia3.  112 
 113 
During aging and disease the BM progressively thickens and stiffens3,4. For example, a 3-fold 114 
increase in the elastic modulus (E) of the ocular BM occurs between the ages of 50 and 80 in 115 
the normal population, and this stiffening is further exacerbated in metabolic disorders like 116 
diabetes5. The structural and biomechanical changes in the BM that result in its increased 117 
stiffness occur when its ECM components, collagen IV and laminin, become non-enzymatically 118 
crosslinked following their exposure to advanced glycation endproducts (AGEs). 119 
 120 
The purpose of the method described here was to establish a model for the investigation of 121 
how BM stiffness, due to AGE exposure, promotes prostate epithelial cell (PEC) and prostate 122 
tumour cell (PTC) invasiveness in the context of the switch to metastatic prostate cancer (PCa). 123 
To do this a previous method used for generating 3D glandular acini from mammary epithelial 124 
cells (MECs) in reconstituted rBM gels6 was adapted to include an additional step where the 125 
rBM gels are pre-treated with glycolaldehyde (GLA). Several techniques for assessing GLA 126 
induced crosslinking and stiffening of pre-treated rBM gels are described, including photometric 127 
analysis, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE), confocal 128 
microscopy and rheometric analysis. The prostate cell types selected for culture on the pre-129 
stiffened rBM include: RWPE-1, PECs derived from a normal prostate gland7; BPH-1, PECs 130 
derived from a prostate gland affected by BPH8; and PC3, metastatic PTCs derived from a 131 
secondary tumor located in the vertebral bone of a prostate cancer (PCa) patient9.  132 
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 133 
In addition to advancing the study of prostate gland pathology, the protocol for stiffening of 134 
rBM gels by their treatment with GLA can be adapted to investigate how BM stiffness 135 
contributes to other age-related pathologies and metabolic disorders. For example, the model 136 
can be directly applied to investigate how metastatic cancer is induced by BM stiffness in 137 
organs such as the breast, colon, ovary and pancreas by the incorporation of appropriate cell 138 
types. Furthermore, the protocol can be adapted to investigate how stiff BM promotes 139 
biomechanical mechanisms of disease progression in diabetes-related microvascular disease, 140 




1. Induction of BM stiffness induced by GLA treatment (non-enzymatic crosslinking) 145 
1.1) Thaw a frozen vial of BM matrix (10 mL) by incubating at 4 °C (standing on ice in a cold 146 
room or refrigerator) until the contents of the vial have become liquid (8-16 hr).  147 
Caution: If a cold room/refrigerator is not used, cover the entire bottle with ice. This will 148 
prevent the stock solution of BM from solidifying. 149 
1.2) For future experiments and to avoid repeated freeze thaw cycles, prepare 25 X 0.4 mL 150 
aliquots from each new 10 mL vial of BM matrix. Store vials at -80 °C until the expiry date 151 
indicated by the manufacturer. When needed, thaw vials at 4 °C standing on ice for 2 hr. 152 
1.3) Prepare an even surface of ice. Place an 8-well chamber glass slide on top of the ice to 153 
maintain a temperature of 4 °C during the coating procedure. Thaw a vial of BM matrix at 4 °C.  154 
Note: One 0.4 mL vial of BM matrix is sufficient to coat an entire 1 X 8-well chamber slide. Keep 155 
the vial covered in ice while handling to prevent the BM matrix from solidifying.  156 
1.4) Cut off the dispensing end of a 200 µL pipette tip using scissors. Cool the blunt-ended 157 
200 µL pipette tip to 4 °C and place it on to a 200 µL capacity pipetting aid. Take up 40 µL of the 158 
cold BM matrix solution into the pipette tip and transfer it into a well on the chilled 8-well 159 
chamber glass slide. 160 
Note: 40 µL of BM solution is enough to cover a surface area of 0.8 cm2. Keep pipette tips 161 
chilled during the coating procedure to avoid solidification of the BM solution. Do not introduce 162 
air bubbles into the BM matrix solution and ensure the well is evenly coated without the 163 
formation of a visible meniscus at the edges.  164 
1.5) Repeat step 1.4 according to the number of wells and chambers required.  165 
1.6) After coating, place the 8-well chamber slide at 37 °C for 30 min to promote 166 
polymerization of the BM. Close the incubator door very carefully to avoid unwanted 167 
disturbance of the liquid rBM. Do not exceed the 30 min incubation time to avoid dehydration 168 
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of the rBM gel. 169 
Note: The resulting gel is the native reconstituted BM (rBM). The 37 °C incubation step does not 170 
require 5 % CO2. However, for convenience perform this step in a tissue culture incubator set at 171 
37 °C and 5 % CO2 (with humidification).  172 
1.7) Prepare 50 mM glycolaldehyde (GLA) diluted in 0.2 M phosphate buffer (pH 7.8). 173 
Sterilize the solution by passing it through a 0.22 micron syringe filter using a 50 mL syringe. 174 
1.7.1) For a crosslinking reaction in a final volume of 250 µL of 50 mM GLA, add 25 µL of 0.5 M 175 
sodium cyanoborohydride or 2.5 M aminoguanidine to 125 µL of 100 mM GLA (2X stock) and 176 
100 µL of 0.2 M phosphate buffer (pH 7.8). Sterilize the stock solutions by passing them through 177 
a 0.22 micron syringe filter using a 50 mL syringe. 178 
 179 
Caution: Handle sodium cyanoborohydride wearing a lab coat, gloves, faceshield and respirator 180 
while working in a fume hood. 181 
1.8) Add 250 µL of GLA solution to cover the polymerized rBM gel and incubate at 37 °C for 6 182 
hr to produce a semi-stiff rBM gel or 14 hr to produce a stiff rBM gel.  183 
Note: The volume of GLA added must cover the polymerized rBM gel and should be adjusted 184 
accordingly. If different GLA incubation times are used, the rBM gels should be analyzed to 185 
determine the fold-increase in rBM stiffness (see Step 2.4).  186 
1.8.1) Prepare a negative control by incubating a native rBM gel in 250 µL of sterile phosphate 187 
buffered saline (PBS) for 14 hr at 37 °C. 188 
1.8.2) Prepare two additional controls where the formation of Schiff base or Amadori adduct 189 
rearrangement during the crosslinking reaction are inhibited, by the addition of 50 mM sodium 190 
cyanoborohydride or 250 mM aminoguanidine.  191 
1.9) Prepare 1 M glycine ethyl ester (GEE) diluted in PBS. Sterilize the solution by passing it 192 
through a 0.22 micron syringe filter using a 50 mL syringe. 193 
1.10) After the indicated incubation time, carefully remove the GLA solution from the 194 
crosslinked rBM gels, GLA solution containing inhibitors from the control rBM gels and PBS from 195 
the control native rBM gels. Add 250 µL of GEE solution to all of the rBM gels and incubate at 37 196 
°C for 1 hr. 197 
Note: This step quenches the crosslinking reaction.  198 
1.11) Wash all rBM gels 10 times in 500 µL PBS to remove all traces of GLA and GEE. Incubate 199 
the rBM gels overnight at 37 °C in 400 µL of PBS to prevent their dehydration.  200 
1.11.1) Analyze the rBM gels for AGE accumulation, non-enzymatic crosslinking and viscoelastic 201 
properties (Steps 2.1 – 2.4). For rheometric analysis of their viscoelastic properties prepare the 202 
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rBM gels in cloning rings (Step 2.4). 203 
1.11.2) For cell culture, rinse rBM gels 2 times with 500 µL culture media before seeding the 204 
cells (Steps 5 and 6). Perform washes gently without the pipette tip touching the gel surface.  205 
2. Quantification of non-enzymatic crosslinking and stiffness of rBM treated with GLA 206 
2.1) Photometric analysis 207 
2.1.1) Measure AGE accumulation in GLA-treated and control rBM gels using photometric 208 
analysis to determine the extent of the Maillard reaction.  209 
2.1.1.1) After Step 1.11, remove the PBS from rBM gels in the 8-wells chamber slides and add 210 
250 µL ice-cold double distilled water. Incubate at 4 °C for 16-24 hr to ensure that the matrix is 211 
completely liquefied.  212 
Note: rBM peptides in this solution contain AGEs with auto-fluorescent properties. 213 
2.1.1.2) Transfer the liquefied BM solution to a 1.5 mL tube and measure the fluorescent 214 
emission of the solution using a spectrophotometer (excitation wavelength = 370 nm; emission 215 
wavelength = 440 nm).  216 
2.2) SDS-PAGE analysis of cyanogen bromide peptides 217 
2.2.1) Resolve the GLA-treated and control rBM gels on a polyacrylamide gel to confirm that 218 
GLA has induced crosslinking and the formation of macro-fibres.  219 
2.2.1.1) Centrifuge the liquefied BM solution collected at Step 2.1.1.2 at 10,000 x g for 5 min at 220 
room temperature. 221 
 222 
2.2.1.2) Prepare a stock solution containing 2 g/mL of cyanogen bromide diluted in acetonitrile.  223 
 224 
Caution: Always handle cyanogen bromide in a fume hood while wearing a lab coat, gloves, 225 
faceshield and respirator. 226 
 227 
2.2.1.3) Remove the supernatant, re-suspend the BM gel pellet in 500 µL of 20 mg/mL 228 
cyanogen bromide + 70 % v/v formic acid and incubate overnight at room temperature.  229 
2.2.1.4) Use a 1 mL disposable syringe to transfer the resuspended BM gel pellet into a dialysis 230 
cassette with a molecular weight cut off 3.5 kDa.  231 
2.2.1.5) Submerge the cassette into a 500 mL glass beaker containing 500 mL of double distilled 232 
water and a magnetic stir bar. Place this onto a magnetic stirrer and dialyze overnight (16 hr) at 233 
4 °C (in a cold room) to remove all traces of cyanogen bromide and formic acid.  234 
2.2.1.6) Use a 1 mL disposable syringe to transfer the dialyzed BM solution from the cassette 235 
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into a 1.5 mL tube.  236 
2.2.1.7) Analyse 25 µL of each BM sample on a 12% v/v polyacrylamide gel10,11. Following SDS-237 
PAGE, carry out silver staining of the polyacrylamide gel12 to visualize the electrophoretic 238 
pattern of cyanogen bromide-matrix peptides13. 239 
2.3 Immunofluorescent microscopy analysis 240 
2.3.1) Perform immunofluorescent staining of GLA treated and control rBM gels with anti-241 
AGE/pentosidine, anti-collagen IV and anti-laminin antibodies followed by confocal microscopy 242 
to visualize accumulated AGEs and collagen IV/laminin fibre structural rearrangements in the 243 
crosslinked rBM gels13.  244 
Note: Always use a sufficient volume to cover the entire rBM gel during incubations and washes 245 
without touching the rBM surface with the pipette tip. For details of analyzing 3D acini cultures 246 
by immunofluorescence see 6 and for confocal microscopy of 3D acini see 14. 247 
2.3.1.1) Wash GLA treated and control rBM gels in 8-wells chamber slides 2 times with 300 µL 248 
of PBS+ (PBS containing 0.1 mM CaCl2 and 0.5 mM MgCl2) for 5 min at room temperature.  249 
2.3.1.2) Remove the PBS+ then add 300 µL of 4 % w/v paraformaldehyde (PFA) diluted in PBS+ 250 
to cover each rBM gel. Incubate for 30 min at room temperature to fix the rBM components.  251 
2.3.1.3) Remove the 4 % w/v PFA solution. Add add 300 µL of 75 mM NH4Cl + 0.5 mM MgCl2 252 
solution and incubate for 5 min at room temperature (repeat 5X) to quench the fixation.  253 
2.3.1.4) Prepare Immunofluorescence buffer (IF buffer) by making the following solution in 254 
sterile water: 130 mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, 7.7 mM NaN3, 0.1% w/v bovine 255 
serum albumin, 0.5% v/v polyethylene glycol tert-octylphenyl ether and 0.05% v/v polyethylene 256 
glycol sorbitan monolaurate.  257 
2.3.1.5) Prepare IF blocking buffer by supplementing IF buffer with 20 % v/v goat serum. 258 
2.3.1.6) Remove the quenching solution and add 300 µL of IF blocking buffer to the rBM gels to 259 
prevent nonspecific reactions. Incubate 2 hr at room temperature on a shaking platform. 260 
2.3.1.7) Remove the IF blocking buffer and incubate the rBM gels for 16 hr at 4 oC with 300 µL 261 
of primary antibody diluted in IF blocking buffer (1: 500 mouse anti-pentosidine mAb; 1/250 262 
rabbit anti-collagen IV pAb; 1/250 rabbit anti-laminin A/C pAb).  263 
Note: Incubations for longer than 20 hr at 4 oC can liquidize the rBM.  264 
2.3.1.8) Remove the primary antibody and wash 3 times (10 min each) with 300 µL of IF 265 
buffer at room temperature on a shaking platform.  266 
2.3.1.9) Remove the IF buffer and add 300 µL of the secondary antibody (goat anti-rabbit 267 
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or anti-mouse IgG [H+L]) conjugated with a fluorochrome diluted 1: 500 in IF blocking buffer. 268 
Incubate for 2 hr at room temperature on a shaking platform.  269 
2.3.1.10) Remove the secondary antibody and incubate in 300 µL of IF buffer for 10 min at 270 
room temperature. Remove the IF buffer and wash 3 X 10 min in 300 µL of PBS+ at room 271 
temperature.  272 
2.3.1.11) Fix and quench a second time, as described above (Steps 2.3.1.2 and 2.3.1.3).  273 
2.3.1.12) Mount stained rBM gels in mounting media and analyze the formation of dense 274 
bundles of major components using epifluorescent or confocal microscopy.  275 
Note: For details of analyzing 3D acini cultures by immunofluorescence see 6 and for 276 
epifluorescent and confocal microscopy of 3D acini see 14. 277 
2.4) Rheological analysis 278 
2.4.1) Perform rheometric analysis of GLA treated and control rBM gels to measure their 279 
viscoelasticity (stiffness). 280 
2.4.1.1) Set up rBM gels that are 1 mm thick in a circular mold with a diameter of 8 mm. To do 281 
this, place a cloning ring (8 mm diameter) inside a well of a 24-well culture plate and add BM 282 
matrix solution prepared as described in Steps 1.3-1.6.  283 
Note: For accurate recapitulation of the rBM gels used for experiments, the rBM gels prepared 284 
for rheometric analysis need to have the same surface area and thickness as the rBM gels set 285 
up in the 8-well chambers. The rBM gels analyzed in Figure 3 were 1 mm thick and 8 mm in 286 
diameter.  287 
2.4.1.2) Treat the rBM gels set up in the cloning rings with PBS, GLA for 6 h and GLA for 14 h as 288 
described above (Steps 1.8 to 1.11). 289 
2.4.1.3) Measure the elastic modulus (E) of the 8 mm diameter rBM gels on a rheometer with 290 
an 8 mm parallel plate serrated geometry, over a range of 1 - 3% strain, at a fixed frequency 291 
oscillation of 1Hz and temperature of 21 °C. For additional details about the rheometric analysis 292 
of ECM gels see references see 13,15,16. 293 
Note: E is determined from the resulting shear storage modulus (G’) through the use of the 294 
following equation E = 2 * G’ * (1+v) where v is the Poisson’s ratio of 0.5, as described in 13,15,16.  295 
3. Culture and handling of the normal PEC line, RWPE-1 296 
3.1) Grow RWPE-1 cells in keratinocyte serum-free media (KSFM) supplemented with 5 297 
ng/mL epidermal growth factor (EGF), 50 μg/mL bovine pituitary extract (BPE) and 50 U/mL 298 
penicillin with 50 μg/mL streptomycin (complete KSFM).  299 
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Note: To avoid induction of epithelial-to-mesenchymal (EMT)-like transition do not expose 300 
RWPE-1 cells to serum. Allow complete KSFM to reach room temperature for 30 min after 301 
removing from storage at 4 °C and do not warm in a 37 °C water bath as this will inactivate the 302 
EGF and BPE. 303 
3.2) Aspirate the complete KSFM from a confluent 10 cm2 plate of RWPE-1 cells, rinse with 5 304 
mL of pre-warmed PBS and add 5 mL of 0.05 % v/v trypsin ensuring that all cells are covered 305 
with the solution.  306 
3.2.1) Place the cells in a tissue culture incubator set at standard conditions of 37 °C and 5% CO2 307 
(with humidification) for 5 to 10 min. Check the extent of trypsinization after 5 min and gently 308 
tap the culture plate to detach the cells.  309 
Note: RWPE-1 cells do not tolerate long periods of trypsinization so it is advised not to handle 310 
more than two plates at the same time. It is also important to dissociate all cells from the plate 311 
to avoid clonal selection. 312 
3.3) When all RWPE-1 cells have disassociated, add 5 mL of warm PBS containing 2 % v/v 313 
fetal calf serum (FCS) to quench the trypsin. Gently pipette up and down to break up the cell 314 
aggregates before transferring the cells to a centrifuge tube. 315 
3.4) Centrifuge the disassociated cells at 125 - 150 x g for 5 min at 25 °C, discard the 316 
supernatant and re-suspend the pellet of cells in 5 mL of complete KSFM until a suspension of 317 
single cells is obtained.  318 
3.5) Transfer 1 mL of the re-suspended cells into a new tube and add 9 mL of complete KSFM 319 
to propagate the cells at a 1:5 passage dilution for subsequent experimental use. Count the rest 320 
of the cells using a hemocytometer for setting up acini (see Section 5.1).  321 
Note: Do not culture RWPE-1 cells for more than 10 passages since after prolonged periods of 322 
culture they do not form acini with the correct architecture. 323 
3.6) Change the culture media every 48 hr to ensure the EGF and BPE remain active.  324 
Note: Include this medium change for any treatments that extend beyond 48 hr.  325 
4. Culture and handling of the BPH cell line, BPH-1 326 
4.1) Culture BPH-1 cells in RPMI 1640 media complemented with 5 % v/v FCS, 50 U/mL 327 
penicillin and 50 μg/mL streptomycin. Warm the culture media, PBS and 0.25% w/v trypsin-0.53 328 
M EDTA solution to 37 °C before use. Note: Cells can also be cultured in media with 2.5 % v/v 329 
FCS8. 330 
4.2) Aspirate the culture media from a confluent 10 cm2 plate of BPH-1 cells and wash the 331 
cells 2 X with 3 mL of PBS to remove all the traces of culture media with serum that may quench 332 
the trypsin reaction.  333 
   
Page 10 of 17          
4.3) Aspirate the PBS and add 3 mL of trypsin-EDTA solution to cover the cells. Place the 334 
plate in an incubator set at 37 °C and 5% CO2 (with humidification) for 5 min. Remove the 335 
trypsin-EDTA solution when the cells are round but remain attached to the dish. Wash cells 336 
with 5 mL of PBS. 337 
4.4) After removal of the PBS, add 5 mL of culture media and gently pipette up and down to 338 
produce a suspension of single cells. Transfer the cells to a 15 mL tube.  339 
4.5) Take 2 mL of the cell suspension into a new centrifuge tube with 8 mL of complete 340 
media and plate the BPH-1 cells onto a 10 cm2 culture plate at a 1:5 passage dilution for 341 
subsequent experimental use. Count the rest of the cells using a hemocytometer for setting up 342 
acini (see Section 5.2).  343 
Note: Keep a record of the passage number, as older BPH-1 cells do not form acini with a 344 
proper architecture. A passage number more than 10 is not desired. 345 
4.6) Change the culture media every 72 hr. 346 
5. 3D culture of prostate gland acini on native and stiff rBM 347 
5.1)  If RWPE-1 cells are being used to form acini, dilute 5,000 cells prepared in step 3.5 in 348 
300 µL of complete KSFM supplemented with 2 % v/v of BM solution. 349 
5.2) If BPH-1 cells are being used to form acini, dilute 2,500 cells prepared in step 4.5 in 300 350 
µL of RPMI 1640 culture media supplemented with 2 % v/v of BM solution.  351 
Note: BPH-1 cells are larger than RWPE-1 cells so lower numbers of BPH-1 cells are used to 352 
obtain a similar distribution of acini after 6 days of culture.  353 
5.3) Gently seed the cells onto the native and AGE-stiffened rBM and carefully place the 354 
cultures in an incubator set at 37 °C and 5% CO2 (with humidification) to ensure an even 355 
distribution of growing acini in the well and that each cell divides to produce one acina.  356 
5.4) Every 2 days replace the culture media with fresh culture media containing 2 % v/v BM 357 
solution to ensure that cells have the growth factors required for normal acina homeostasis.  358 
5.5) Monitor acinar morphology in growing cultures using brightfield microscopy13.  359 
Note: After 3 days in culture individual cells will form a cluster of >3 cells and after 1 week 360 
prostate gland acini with a diameter of ~50 µm will be observed. 361 
5.6) Follow protocol described in 2.3 to perform immunofluorescence using antibodies 362 
specific for markers of cell-matrix adhesions, cell-cell adhesions, apico-basal polarity and 363 
invasiveness13.  364 
5.6.1) Use a mounting media with 4',6-diamidino-2-phenylindole (DAPI) or include an extra step 365 
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(after 2.3.12) to stain cell nuclei by incubating with DAPI for 5 min and wash 2 X 5 min with 366 
PBS+.  367 
6. 3D culture of prostate tumor cell aggregates on native and stiff rBM 368 
6.1) Culture PC3 cells in RPMI 1640 medium containing 10 % v/v FCS and 50 U/mL penicillin 369 
with 50 μg/mL streptomycin. Warm the culture media, PBS and 0.25 % w/v trypsin-0.53 M 370 
EDTA solution to 37 °C before use. 371 
6.2) Aspirate the culture media from a confluent 10 cm2 culture dish of PC3 cells and wash 372 
the cells 2 X with 3 mL of PBS to remove all traces of FCS that can quench the trypsin reaction. 373 
6.3) Aspirate the PBS and add 3 mL of trypsin-EDTA solution to cover the cells and incubate 374 
for 1 min.  375 
6.4) When the cells become rounded, but remain attached to the dish, carefully aspirate the 376 
trypsin-EDTA solution and wash with 3 mL of PBS to remove all traces of trypsin. 377 
6.5) After removal of the PBS, add 5 mL of culture media and gently pipette up and down to 378 
produce a suspension of single cells. Transfer the cells to a 15 mL tube.  379 
6.6) Take 1 mL of the PC3 cell suspension into a new centrifuge tube and add 9 mL of culture 380 
media. Plate the cells on a 10 cm2 culture dish (1:10 dilution) for subsequent experimental use. 381 
Count the remaining cells using a hemocytometer. 382 
6.7) Dilute 2,500 PC3 cells prepared in step 6.6 in 300 µL of RPMI 1640 culture media 383 
supplemented with 2 % v/v of BM solution to allow for the formation of a gradient gel in the 384 
culture.  385 
6.8) Gently seed the cells onto the native and AGE-stiffened rBM and carefully place the 386 
culture into the incubator set at 37 °C and 5% CO2 (with humidification) to ensure even 387 
distribution of growing spheroids in the well. 388 
6.9) Change the culture media every 72 hr.  389 
6.10) To study the effect of stiff (AGE-rich) rBM on prostate tumor cell migration, image PC3 390 
cells using brightfield video time-lapse microscopy using temperature/CO2 control and a 391 
humidified chamber17.  392 
Note: PC3 cells grow in strands on native rBM and do not form acini with a lumen, but if left to 393 
grow more than 72 hr on native rBM they will form 3D spheroids.  394 
6.11) Following data acquisition, manually track PC3 cells and calculate their migration speed, 395 
shape (elongation ratio) and persistence of migration17-19.  396 
Note: Persistence = ratio D/T, D = distance from start to end of cell trajectory, T= total length of 397 
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cell trajectory. 398 
REPRESENTATIVE RESULTS:  399 
3D prostate acini cultured on stiff rBM: 400 
After 6 days in culture, PECs derived from normal prostate tissue (RWPE-1) (Figure 1A) and BPH 401 
tissue (BPH-1) (Figure 1B) form acini on native (PBS treated) rBM that are organized into 402 
uniform spheroids of epithelial cells. These acini also have the characteristics of highly 403 
organized PECs with apical-to-basal polarity and a visible luminal space13,20.  404 
 405 
The acini formed by PECs derived from normal prostate tissue (RWPE-1) (Figure 1A) and BPH 406 
tissue (BPH-1) (Figure 1B) on stiffened (AGE-rich) rBM (treated with GLA) have a disrupted 407 
architecture (shifting from spheroidal to polygonal in shape and cells protruding/migrating from 408 
the acini into the AGE-rich rBM) (Figure 1A). These acini are also characterized by highly 409 
disorganized PECs that have lost their apical-to-basal polarity with a small or non-existent 410 
luminal space13.  411 
 412 
[Place Figure 1 here] 413 
 414 
[Place Table 1 here] 415 
 416 
AGE dependent increased rBM stiffness promotes PC3 prostate tumor cell migration: 417 
PC3 cells grown on native rBM migrate by maintaining continuous cell-cell contact, whereas 418 
PC3 cells grown on AGE-rich (stiff) rBM move independently from each other (Figure 2A). After 419 
72 hr in culture PC3 cells form foci (spheroids) on native (PBS treated) rBM, whereas PC3 cells 420 
on stiff (AGE-rich) rBM do not from spheroids and migrate independently (Figure 2B). PC3 cells 421 
on stiff (AGE-rich) rBM are more elongated than PC3 cells grown on native rBM (Figure 2C). PC3 422 
cells on stiff rBM migrate faster than PC3 cells grown on native rBM (Figure 2D). PC3 cells on 423 
stiff rBM display a decrease in persistence compared to PC3 cells grown on native rBM (Figure 424 
2E). 425 
 426 
[Place Figure 2 here] 427 
 428 
Figure 1: Prostate epithelial cells grown as 3D glandular acini on native and stiff reconstituted 429 
basement membrane (rBM). A. Brightfield images of RWPE-1 cells grown for 12 hr up to 6 days 430 
on rBM gels treated with PBS (native) or 50 mM glycolaldehyde for 14 hr (AGE-rich; stiff); scale 431 
bar = 50 μm. B. BPH-1 cells, grown as described in panel A; scale bars = 50 μm; data is 432 
representative of 3 independent experiments. 433 
 434 
Figure 2: Prostate tumor cell migration on native and stiff reconstituted basement membrane 435 
(rBM). A. Brightfield images of PC3 cells grown on rBM gels treated with PBS (native) or 50 mM 436 
glycolaldehyde for 14 hr (AGE-rich, stiff). Cells were imaged using a brightfield microscope (10 X 437 
objective) and an acquisition rate of 1 image per h for 12 hr followed by cell tracking to 438 
generate trajectories. Images shown correspond to the time points after 0, 3, 6, 9 and 12 hr. 439 
Trajectories of single cells are shown for the 12 hr time point. Scale bar = 100 µm. B. PC3 cells 440 
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cultured on native or stiff rBM for 72 hr, and imaged as described in panel A. Scale bar = 100 441 
µm. Detail shows selected area at 2 X magnification. C. Mean ± S.D. cell length (µm); significant 442 
difference between native rBM and stiff rBM (p = 1.2 x 10-23). D. Mean ± S.D. velocity (µm/sec) 443 
calculated from cell trajectories; significant difference between native rBM and stiff rBM (p = 444 
0.004). E. Mean ± S.D. persistence of cell movement (ratio D/T, where D = distance from start to 445 
end of cell trajectory, T = total length of cell trajectory); significant difference between native 446 
rBM and stiff rBM (p = 0.0007). For panels C-E > 10 cells were analyzed, data is representative 447 
of 3 independent experiments.  448 
 449 
Figure 3: Overview of the different protocols presented here. The diagram depicts how to 450 
prepare and stiffen the reconstituted basement membrane (rBM) with glycolaldehyde (Maillard 451 
reaction), how to seed cells on to the stiff rBM, how to analyze the stiff rBM (extent of Maillard 452 
reaction) and procedures that can be used to analyze the cellular and molecular changes 453 
induced by AGE-rich rBM. AGE, advanced glycation endproducts; BM, basement membrane; 454 
DAPI, 4',6-diamidino-2-phenylindole; EEA1, early endosomal antigen 1; GAPDH, glyceraldehyde-455 
3-phosphate dehydrogenase; GLA, glycolaldehyde; GEE, glycine ethyl ester; GM130, 130 kDa 456 
cis-Golgi marker; p-MLC2 (Thr18/Ser19), myosin light chain-2 phosphorylated at sites threonine 457 
18 and serine 19; rBM, reconstituted basement membrane; SDS-PAGE, sodium dodecyl sulfate 458 
polyacrylamide gel electrophoresis. For RWPE1 acini scale bar = 10 µm; for PC3 tumor cell 459 
spheroids scale bar = 100 µm. This figure has been modified from13. 460 
 461 
Figure 4: Simple overview of the protocol with critical steps and timings indicated. The flow 462 
diagram depicts how to prepare and stiffen the reconstituted basement membrane (rBM) with 463 
glycolaldehyde (Maillard reaction) with critical steps and timings indicated. Points where the 464 
protocol can be stopped, and rBM gels stored, are also indicated. rBM, reconstituted basement 465 
membrane; GLA, glycolaldehyde; GEE, glycine ethyl ester.  466 
 467 
Table 1: Characteristics of prostate epithelial RWPE-1 acini grown on native, semi-stiff and 468 
stiff reconstituted basement membrane (rBM). RWPE-1 acini were grown on rBM pre-treated 469 
with PBS for 14 h (native), glycolaldehyde (GLA) for 6 hr (semi-stiff) or GLA for 14 hr (stiff). For 470 
acinar shape, the percentage (%) ± standard deviation (SD) of round, semi-polygonal and 471 
polygonal acini were calculated from 5 independent experiments (50 acini quantified per 472 
condition). Relative acinar size was calculated (native rBM = 100 %) from 3 independent 473 
experiments. For invasiveness, % ± SD acini with one or more protruding cells were calculated 474 
from 3 independent experiments. Fold change is calculated by dividing the average value 475 
obtained under semi-stiff or stiff conditions by the corresponding value for native conditions. P 476 
values calculated using Student’s t-test ( = 0.05).  477 
 478 
DISCUSSION: 479 
A protocol for the generation of 3D glandular acini from MECs in pure rBM gels6 was modified 480 
in a previous study by the addition of 4 mg/mL type I collagen to the rBM matrix. The addition 481 
of collagen resulted in the elastic modulus of the rBM gel increasing from 175 ± 37 to 1589 ± 482 
380 Pascals. This 9.1-fold increase in stiffness modulated the growth, survival, migration and 483 
differentiation of MECs21. The protocol was modified again by including a treatment step with 484 
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D-(-)-ribose to promote non-enzymatic crosslinking of the type I collagen that had been added 485 
to the rBM gel. The resultant 15-fold increase in stiffness was found to cooperate with 486 
oncogenic transformation of MECs to promote their invasive behavior22. The experimental 487 
approach of adding type I collagen to rBM gels facilitates the direct interaction of MECs with 488 
collagen fibres, which only occurs in human tissue after the physical barrier between the 489 
stroma and epithelium provided by the BM undergoes proteolytic degradation. By generating 490 
3D glandular acini from PECs in pure rBM gels pre-treated with GLA, the current protocol opens 491 
the way to study how BM stiffness per se can trigger their invasive behaviour (Figure 3). The 492 
levels of BM stiffness induced in this protocol have physiological relevance. Incubation with 50 493 
mM GLA for 6 hr and 14 hr respectively increased the elastic moduli of the pure rBM gel to 175 494 
± 90 and 322 ± 160 compared to 122 ± 55 Pascals in rBM gels treated with PBS (Table 1). This 495 
1.7 to 3.2-fold increase in rBM stiffness recapitulates the 2.5- to 3.4-fold increase in stiffness 496 
observed in malignant compared to normal prostate or BPH tissue23-26. As outlined in a recent 497 
publication13 the morphological changes induced by the accumulation of AGE and rBM stiffness 498 
in PEC acini can be quantified for a statistically significant shift from a rounded to polygonal 499 
shape, decreased luminal/total acinar area, and protruding cells migrating from the acina into 500 
the AGE-rich rBM (Figure 3). Immunoblotting can also be used to assess markers of EMT (e.g. 501 
loss of E-cadherin13) and  the contractile behavior (e.g. phosphorylated myosin light chain-2, 502 
pMLC213) in PECs grown in normal versus stiff rBM (Figure 3). Further evaluation using 503 
immunofluorescent staining and confocal microscopy can be applied to visualize the BM (e.g. 504 
laminin, collagen IV and AGE accumulation13), cellular apical-to-basal polarity (e.g. apical 505 
localization of EEA1: early endosomal antigen 1; and GM130: 130 kDa cis-Golgi marker13) and 506 
cellular patterns of adhesion molecules (e.g. E-cadherin localization to cell-cell junctions13) 507 
(Figure 3). 508 
 509 
[Place Figure 3 here] 510 
 511 
Troubleshooting steps will be necessary if D-(-)-ribose is chosen as the crosslinking agent for 512 
rBM. During protocol development it was found that treatment with 1 M D-(-)-ribose for 72 hr, 513 
as previously described for rBM/collagen gels22, resulted in the dehydration and shrinkage of 514 
rBM gels. The evaluation of lower concentrations of D-(-)-ribose and shorter treatment times 515 
may help to overcome this limitation. If longer incubation times and higher concentrations of 516 
GLA are used to induce higher levels of rBM gel stiffness it will be necessary to assess whether 517 
these treatment conditions have an impact on cell survival and proliferation, as previously 518 
described13.  519 
 520 
When RWPE-1 cells are exposed to serum or serum-containing materials they adopt an EMT-521 
like phenotype. For this reason short interfering RNA (siRNA) oligonucleotide treatment needs 522 
to be optimized in KSFM. If gene-silencing efficiency is compromised inducible shRNA vectors 523 
should be employed to overcome this limitation.  524 
 525 
This protocol will facilitate the future study of pro-invasive mechanisms triggered by AGE-526 
dependent BM stiffness in PECs (RWPE-1, BPH-1) and evaluation of anti-metastatic targets in 527 
invasive PTCs (PC3). Given that BPH is considered to be a metabolic disorder27, this protocol 528 
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also paves the way towards our improved understanding of the link between metabolic 529 
disorders and increased prostate cancer risk. Given that BM stiffness induced by its exposure to 530 
AGEs may be a trigger for invasiveness in other cancer types, it will be of interest to use the 531 
protocol to set up similar models that incorporate normal epithelial cells and tumor cells from 532 
other organs (e.g. breast, colon, ovaries, pancreas).  533 
 534 
Critical steps within the protocol, together with their timings, are summarized in Figure 4.  535 
 536 
[Place Figure 4 here] 537 
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